CF
UNCY icon

Cantor Fitzgerald’s Unicycive Therapeutics UNCY Stock Holding History

Cantor Fitzgerald’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$235K Sell
50,000
-25,000
-33% -$184K ﹤0.01% 313
2026
Q1 		$494K Sell
75,000
-125,000
-63% -$819K 0.01% 220
2025
Q4 		$1.15M Buy
+200,000
New +$1.07M 0.02% 156
2025
Q2 		– Sell
-3,297
Closed -$19K – 541
2025
Q1 		$19K Buy
+3,297
New +$20.1K ﹤0.01% 272

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Cantor Fitzgerald's UNCY Position: Q2 2026 in Review

Cantor Fitzgerald reduced its Unicycive Therapeutics (UNCY) stake by 33% in Q2 2026, selling an estimated $184K and leaving 50,000 shares worth $235K. The position accounts for ﹤0.01% of the portfolio, ranked #313.

Cantor Fitzgerald first reported a position in UNCY in Q1 2025 and has held it in 4 quarters since. The position peaked at $1.15M in Q4 2025. 80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • Cantor Fitzgerald held 50,000 shares of Unicycive Therapeutics worth $235K as of Q2 2026.
  • Cantor Fitzgerald sold 25,000 Unicycive Therapeutics shares in Q2 2026, an estimated $184K.
  • Unicycive Therapeutics made up ﹤0.01% of Cantor Fitzgerald's portfolio in Q2 2026, its #313 holding.
  • Cantor Fitzgerald first reported a position in Unicycive Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • Cantor Fitzgerald's Unicycive Therapeutics position peaked at $1.15M in Q4 2025.
  • 80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Cantor Fitzgerald's 13F filing for Q2 2026, filed 14 Aug 2026.